Predictive performance of the cardiovascular event risk test 2 risk score in hemodialysis patients with ESKD: clinical research : chronic kidney disease

Key Points  - - The Cardiovascular Event Risk Test 2 (CERT2) risk score effectively stratified patients undergoing hemodialysis patients on the basis of their risk of major adverse cardiovascular (CV) event, CV death, and all-cause death. - Patients in the high...

Full description

Saved in:
Bibliographic Details
Main Authors: Witoslawska, Angelika (Author) , Drechsler, Christine (Author) , Duarte, Kevin (Author) , Girerd, Nicolas (Author) , Zannad, Faiez (Author) , Rossignol, Patrick (Author) , Kleber, Marcus E. (Author) , Scharnagl, Hubert (Author) , Wanner, Christoph (Author) , März, Winfried (Author) , Laaksonen, Reijo (Author)
Format: Article (Journal)
Language:English
Published: November 12, 2025
In: Clinical journal of the American Society of Nephrology

ISSN:1555-905X
DOI:10.2215/CJN.0000000831
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.2215/CJN.0000000831
Verlag, lizenzpflichtig, Volltext: https://journals.lww.com/cjasn/fulltext/9900/predictive_performance_of_the_cardiovascular_event.771.aspx
Get full text
Author Notes:Angelika Witoslawska, Christine Drechsler, Kevin Duarte, Nicolas Girerd, Faiez Zannad, Patrick Rossignol, Marcus E. Kleber, Hubert Scharnagl, Christoph Wanner, Winfried März, Reijo Laaksonen

MARC

LEADER 00000naa a22000002c 4500
001 194268715X
003 DE-627
005 20251127105643.0
007 cr uuu---uuuuu
008 251127s2025 xx |||||o 00| ||eng c
024 7 |a 10.2215/CJN.0000000831  |2 doi 
035 |a (DE-627)194268715X 
035 |a (DE-599)KXP194268715X 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Witoslawska, Angelika  |e VerfasserIn  |0 (DE-588)1382811284  |0 (DE-627)1942687761  |4 aut 
245 1 0 |a Predictive performance of the cardiovascular event risk test 2 risk score in hemodialysis patients with ESKD  |b clinical research : chronic kidney disease  |c Angelika Witoslawska, Christine Drechsler, Kevin Duarte, Nicolas Girerd, Faiez Zannad, Patrick Rossignol, Marcus E. Kleber, Hubert Scharnagl, Christoph Wanner, Winfried März, Reijo Laaksonen 
264 1 |c November 12, 2025 
300 |a ? 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 27.11.2025 
520 |a Key Points  - - The Cardiovascular Event Risk Test 2 (CERT2) risk score effectively stratified patients undergoing hemodialysis patients on the basis of their risk of major adverse cardiovascular (CV) event, CV death, and all-cause death. - Patients in the highest CERT2 risk category had a two-fold higher risk of major adverse CV event and all-cause death compared with those in the lowest category. - CERT2 risk score shows that novel lipid-based biomarker solution outperforms regular CV risk biomarkers and existing risk scores in dialysis. - - - Background  - ESKD is closely associated with cardiovascular disease (CVD) primarily because of shared underlying conditions, such as diabetes mellitus and hypertension. Increased levels of circulating ceramide lipids have been linked to major adverse events in CVD, as well as to ESKD. Our aim was to investigate the predictive value of the Cardiovascular Event Risk Test 2 (CERT2) risk score in patients with ESKD in identifying patients at an increased risk of major adverse cardiovascular events (MACEs). - Methods  - This study combines data from 2311 patients from the A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events (AURORA) trial and 1137 patients from the Die Deutsche Diabetes Dialyze Studie (4D) trial. Both studies enrolled patients with ESKD undergoing hemodialysis. The CERT2 risk score has been calculated on the basis of quartile stratification of predefined lipid ratios for all the participants. The primary outcome of interest was MACE with additional outcomes of cardiovascular death and all-cause death. - Results  - After adjusting for traditional CV factors and other variables, two-fold higher risk was reported for MACE for patients in the highest risk category (AURORA: hazard ratios [HRs], 1.98; 95% confidence interval [CI], 1.53 to 2.55; 4D: HR, 1.70; 95% CI, 1.23 to 2.34) in comparison with those in the lowest risk category. Similarly, the two-fold higher risk was also observed for all-cause death for patients in the highest risk category (AURORA: HR, 2.14; 95% CI, 1.72 to 2.66; 4D: HR, 1.78; 95% CI, 1.36 to 2.34). In both trials, the CERT2 risk score demonstrated superior predictive performance compared with traditional markers like LDL cholesterol. In the AURORA cohort, the CERT2 risk score outperformed Systematic Coronary Risk Evaluation 2 and atherosclerotic CVD risk estimators in predicting CV outcomes. - Conclusions  - The CERT2 risk score identifies patients with ESKD who are at a higher risk of MACE and all-cause death. These findings highlight the potential of the CERT2 risk score as a novel lipid-based biomarker for CV risk stratification in patients undergoing hemodialysis, offering improved prognostic performance over existing biomarkers and risk scores. - - - - Visual Abstract - - Export 
700 1 |a Drechsler, Christine  |e VerfasserIn  |4 aut 
700 1 |a Duarte, Kevin  |e VerfasserIn  |4 aut 
700 1 |a Girerd, Nicolas  |e VerfasserIn  |4 aut 
700 1 |a Zannad, Faiez  |e VerfasserIn  |4 aut 
700 1 |a Rossignol, Patrick  |e VerfasserIn  |4 aut 
700 1 |a Kleber, Marcus E.  |d 1974-  |e VerfasserIn  |0 (DE-588)1030135177  |0 (DE-627)734830440  |0 (DE-576)377941379  |4 aut 
700 1 |a Scharnagl, Hubert  |e VerfasserIn  |4 aut 
700 1 |a Wanner, Christoph  |e VerfasserIn  |4 aut 
700 1 |a März, Winfried  |d 1958-  |e VerfasserIn  |0 (DE-588)1027603599  |0 (DE-627)729463605  |0 (DE-576)373454635  |4 aut 
700 1 |a Laaksonen, Reijo  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |a American Society of Nephrology  |t Clinical journal of the American Society of Nephrology  |d Washington, DC : American Society of Nephrology, 2006  |g (2025) vom: Nov.  |h Online-Ressource  |w (DE-627)50595091X  |w (DE-600)2216582-4  |w (DE-576)30683281X  |x 1555-905X  |7 nnas 
773 1 8 |g year:2025  |g month:11  |g extent:?  |a Predictive performance of the cardiovascular event risk test 2 risk score in hemodialysis patients with ESKD clinical research : chronic kidney disease 
856 4 0 |u https://doi.org/10.2215/CJN.0000000831  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext  |7 1 
856 4 0 |u https://journals.lww.com/cjasn/fulltext/9900/predictive_performance_of_the_cardiovascular_event.771.aspx  |x Verlag  |z lizenzpflichtig  |3 Volltext  |7 1 
951 |a AR 
992 |a 20251127 
993 |a Article 
994 |a 2025 
998 |g 1027603599  |a März, Winfried  |m 1027603599:März, Winfried  |d 60000  |d 61400  |d 910000  |d 910100  |e 60000PM1027603599  |e 61400PM1027603599  |e 910000PM1027603599  |e 910100PM1027603599  |k 0/60000/  |k 1/60000/61400/  |k 0/910000/  |k 1/910000/910100/  |p 10 
998 |g 1030135177  |a Kleber, Marcus E.  |m 1030135177:Kleber, Marcus E.  |d 60000  |d 61400  |e 60000PK1030135177  |e 61400PK1030135177  |k 0/60000/  |k 1/60000/61400/  |p 7 
999 |a KXP-PPN194268715X  |e 4814767552 
BIB |a Y 
SER |a journal 
JSO |a {"id":{"eki":["194268715X"],"doi":["10.2215/CJN.0000000831"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"? S."}],"relHost":[{"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Clinical journal of the American Society of Nephrology","subtitle":"CJASN","title":"Clinical journal of the American Society of Nephrology"}],"disp":"American Society of NephrologyClinical journal of the American Society of Nephrology","note":["Gesehen am 04.08.2025"],"corporate":[{"role":"aut","display":"American Society of Nephrology"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"eki":["50595091X"],"zdb":["2216582-4"],"issn":["1555-905X"]},"pubHistory":["1.2006 -"],"part":{"text":"(2025) vom: Nov.","extent":"?","year":"2025"},"titleAlt":[{"title":"CJASN"}],"recId":"50595091X","origin":[{"dateIssuedDisp":"2006-","publisher":"American Society of Nephrology","dateIssuedKey":"2006","publisherPlace":"Washington, DC"}]}],"title":[{"title_sort":"Predictive performance of the cardiovascular event risk test 2 risk score in hemodialysis patients with ESKD","subtitle":"clinical research : chronic kidney disease","title":"Predictive performance of the cardiovascular event risk test 2 risk score in hemodialysis patients with ESKD"}],"language":["eng"],"person":[{"role":"aut","display":"Witoslawska, Angelika","given":"Angelika","family":"Witoslawska"},{"display":"Drechsler, Christine","role":"aut","family":"Drechsler","given":"Christine"},{"given":"Kevin","family":"Duarte","role":"aut","display":"Duarte, Kevin"},{"given":"Nicolas","family":"Girerd","role":"aut","display":"Girerd, Nicolas"},{"given":"Faiez","family":"Zannad","role":"aut","display":"Zannad, Faiez"},{"display":"Rossignol, Patrick","role":"aut","family":"Rossignol","given":"Patrick"},{"role":"aut","display":"Kleber, Marcus E.","given":"Marcus E.","family":"Kleber"},{"given":"Hubert","family":"Scharnagl","role":"aut","display":"Scharnagl, Hubert"},{"family":"Wanner","given":"Christoph","display":"Wanner, Christoph","role":"aut"},{"given":"Winfried","family":"März","role":"aut","display":"März, Winfried"},{"display":"Laaksonen, Reijo","role":"aut","family":"Laaksonen","given":"Reijo"}],"origin":[{"dateIssuedDisp":"November 12, 2025","dateIssuedKey":"2025"}],"name":{"displayForm":["Angelika Witoslawska, Christine Drechsler, Kevin Duarte, Nicolas Girerd, Faiez Zannad, Patrick Rossignol, Marcus E. Kleber, Hubert Scharnagl, Christoph Wanner, Winfried März, Reijo Laaksonen"]},"recId":"194268715X","note":["Gesehen am 27.11.2025"]} 
SRT |a WITOSLAWSKPREDICTIVE1220